Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

About Us

Our Story

Our Story

In April 2018, BWXT announced a ground-breaking technology poised to make a significant, positive impact on the supply reliability of the North American nuclear medicine market. To develop and commercialize this technology, in July 2018, BWXT acquired Sotera Health’s Nordion Medical Isotopes division. Combining the power of innovative technology for Technetium-99m generators and the expertise of an established leader in the nuclear medicine industry formed the foundation of BWXT's nuclear medicine business - BWXT Medical. BWXT's strategic acquisition adds 40 years of industry experience and a world-class product line to our existing capabilities and intellectual property. With our company at the forefront of medical isotope and radiopharmaceutical production, the quality products, high-level service and unwavering commitment that we have previously provided to our customer base will remain unchanged.

Headquartered in Ottawa, Ontario, BWXT Medical Ltd. employs over 250 highly-skilled professionals across both Ottawa and Vancouver, British Columbia. We manufacture custom radiopharmaceuticals, radiotherapies and medical isotopes in our 80,000 ft2 cGMP manufacturing facility in Ottawa and at the state-of-the-art commercial cyclotron facility within TRIUMF, Canada’s particle acceleration centre, in Vancouver.